Viewing nowEmpaloh Tablet 10 mg (Empagliflozin)
Empagliflozin Amorphous 10mg
Tablet · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.

MFDS item code 202102079 · Approved 2021.03.05 · Insurance code 645907220
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapy to help control blood sugar levels in adults with type 2 diabetes. It can be administered as monotherapy and, in cases of poor blood sugar control, can be combined with other medications such as metformin, pioglitazone, sulfonylureas, insulin, and DPP-4 inhibitors. Caution is advised for type 2 diabetes patients with cardiovascular disease, and usage should be closely monitored according to a professional's guidance. This medication effectively improves blood sugar levels and is used for diabetes treatment.
The recommended dose of this medicine is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is required for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is required for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Elderly patients No dose adjustment is required based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age and older. Initiation of this medicine is not recommended in patients 85 years of age and older because clinical experience is limited (see Precautions for Use, 4. General Precautions).
This medication should not be used by individuals who are allergic to the active ingredient or any component of this medication. This medication is not suitable for patients with type 1 diabetes or diabetic ketoacidosis. Patients with severely impaired kidney function, particularly those with a glomerular filtration rate below 30 mL/min/1.73m2 or with end-stage kidney disease or on dialysis should not take this medication. This medication contains lactose, so individuals with issues breaking down lactose or genetic disorders such as galactose intolerance, Lapp lactose deficiency, and glucose-galactose malabsorption should not use it. This medication should be used cautiously in patients with slightly impaired kidney function, and kidney function should be regularly monitored, with dosage adjustments or discontinuation as necessary. In patients with heart failure, particularly those with mild to moderate severity, caution is required, and it is not recommended for those with severe heart failure. When this medication is used with drugs that can cause hypoglycemia, such as insulins or sulfonylureas, dosage adjustments may be necessary to reduce the risk of hypoglycemia. While taking this medication, keep a close watch for symptoms such as hypoglycemia, urinary tract infections, genital infections, increased urination, and decreased fluid volume since these side effects may occur. Severe metabolic abnormalities such as ketoacidosis may occur, and if symptoms like vomiting, abdominal pain, or respiratory distress are observed, consult healthcare professionals immediately. Elderly patients, especially those over 75 years of age, are at higher risk of fluid loss and should be monitored closely, while use is not recommended for those over 85 years. This medication may increase the risk of serious urinary tract infections such as urosepsis or pyelonephritis, so prompt treatment is necessary if infection symptoms occur. Pregnant women or those planning to become pregnant should avoid using this medication, and breastfeeding mothers should also discontinue breastfeeding. It is not used in children and adolescents due to lack of safety and efficacy data. No specific toxicity has been reported in cases of overdose, but appropriate treatment may be required according to clinical conditions. This medication may have a minor impact on driving or operating machinery, so caution is advised especially in cases of risk of hypoglycemia. Regularly check kidney function and blood sugar levels while taking this medication, and inform healthcare professionals if abnormalities are observed.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container that protects it from air and moisture, and it is best stored at room temperature between 1 degree and 30 degrees Celsius. This will help maintain the effectiveness of the medication.
Light yellow, double-convex, round film-coated tablets
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin Amorphous 10mg
Tablet · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.

Empagliflozin Amorphous 10mg
Tablet · Prescription medication
International Pharmaceuticals Co., Ltd.

Empagliflozin Amorphous 25mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.

Empagliflozin Amorphous 25mg
Tablet · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.